Page 3 - Il 17 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: Immunic, Inc. / Key word(s): Patent Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor 02.02.2022 / 22:01 The issuer is solely responsible for the content of this annou...

DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor 14.12.2021 / 12:30 The issuer is solely responsible for the ...

Affibody and Inmagene autoimmune partnership completes regulatory milestone Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis. Uveitis is an orphan disease with significant unmet medical need. It is an inflammation of the uveal tract but can also include the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. It is one of the leading causes of blindness...